文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]F-Fluciclovine PET/CT在PSMA PET阴性的前列腺癌生化复发患者中的作用

Role of [18F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center Study.
PubMed 文献 · J Nucl Med · 2026-10-29

这项前瞻性单臂研究纳入50例PSA≥0.2 ng/mL且PSMA PET阴性的前列腺癌生化复发患者,在30天内行[18F]F-Fluciclovine PET/CT。结果显示56%的患者检出阳性病灶,其中半数局限于前列腺床、半数为淋巴结或远处转移,检出率随PSA升高而增加,71%的患者治疗意图发生改变。

要点

  • PSMA PET阴性患者中,[18F]F-Fluciclovine PET/CT检出率达56%。
  • 阳性病灶中50%局限于前列腺床,50%为淋巴结或远处转移。
  • 检出率随PSA升高而增加,从44%(0.2-0.5 ng/mL)至100%(≥5 ng/mL)。

核心结论

  • [18F]F-Fluciclovine PET在超过半数PSMA PET阴性的生化复发患者中检出复发灶,并常改变治疗决策,支持其作为特定患者的补充手段。

研究设计与样本

  • 前瞻性单臂研究(NCT05722925),纳入50例PSA≥0.2 ng/mL且PSMA PET阴性的前列腺癌生化复发患者。
  • 患者在先前PSMA PET后30天内接受[18F]F-Fluciclovine PET/CT。

主要发现

  • 50例中28例(56%;95% CI,41%-70%)[18F]F-Fluciclovine PET呈阳性。
  • 阳性患者中14例(50%)病灶局限于前列腺床,14例(50%)有淋巴结或远处转移。
  • 检出率随PSA升高而增加,从PSA 0.2-0.5 ng/mL时的44%升至PSA≥5 ng/mL时的100%。
  • [18F]F-Fluciclovine PET后71%患者治疗意图改变,阳性者中87%、阴性者中54%。
  • 有参考标准的14例患者中,所有阳性发现均证实为真阳性。

关键数值与推荐

  • 生化复发定义为PSA≥0.2 ng/mL。
  • PSMA PET阴性后30天内行[18F]F-Fluciclovine PET/CT。
  • 检出率总体56%(95% CI,41%-70%),PSA 0.2-0.5 ng/mL组44%,PSA≥5 ng/mL组100%。
  • 治疗意图改变率71%(阳性者87%,阴性者54%)。
  • 参考标准可用的14例中,阳性发现真阳性率100%。

临床怎么用

  • 对PSMA PET阴性的生化复发患者,可考虑补充[18F]F-Fluciclovine PET/CT以定位病灶。
  • PSA水平较低(0.2-0.5 ng/mL)时检出率仍达44%,但需结合患者具体情况判断。
  • 该检查结果可能改变治疗意图,尤其阳性患者中87%发生改变。

局限性

  • 单中心、单臂研究,样本量50例。
  • 仅14例有参考标准验证,其余阳性发现未经病理证实。
  • 未报告阴性预测值及长期随访结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to evaluate whether [18F]F-fluciclovine PET/CT detects sites of disease in patients with biochemical recurrence (BCR) of prostate cancer and negative findings on prostate-specific membrane antigen (PSMA) PET and to assess its impact on intended management. Methods: In this prospective single-arm study (NCT05722925), 50 patients with BCR (prostate-specific antigen [PSA] ≥ 0.2 ng/mL) and negative findings on PSMA PET underwent [18F]F-fluciclovine PET/CT within 30 d of the previous imaging. Detection rate, distribution of disease, PSA-stratified analysis, management impact, and correct localization rate were assessed using descriptive statistics and exact CI. Results: [18F]F-fluciclovine PET had positive findings in 28 of 50 patients (56%; 95% CI, 41%-70%). Disease was confined to the prostate bed in 14 patients (50%), whereas 14 (50%) demonstrated nodal or distant metastases. Detection rate increased with PSA, from 44% at a PSA of 0.2-0.5 ng/mL to 100% at a PSA of 5 ng/mL or higher. The intended management changed in 71% of patients after the [18F]F-fluciclovine PET: 87% of patients with positive findings and 54% with negative findings. Among patients with an available reference standard (n = 14), all positive findings were confirmed to be true-positive. Conclusion: [18F]F-fluciclovine PET detected recurrent disease in over half of patients with negative PSMA PET findings and frequently altered management, supporting its complementary role in selected patients with BCR.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Szidonya L, Obrzut S, Lim JY, et al. Role of [18F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center Study. J Nucl Med. 2026. PMID: 42957209. doi:10.2967/jnumed.126.272834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。